FDA Commissioner Martin Makary on Thursday announced a move away from animal-based drug testing in favor of human-based methods and artificial intelligence to determine drug safety and effectiveness.

In future medicine, personalized computer models, so-called Virtual Human Twins, could help in the planning of individual therapies. Today already, human organs can be simulated on chips or in petri ...

The Food and Drug Administration (FDA) announced Thursday it plans to phase out animal testing requirements for biological products and drugs, instead moving toward alternative testing models such ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...

Technical.ly is a free news resource thanks to financial supporters like Certara, a Technical.ly client, which sponsored this article. It was reviewed before publication. Learn more about Certara.

Please provide your email address to receive an email when new articles are posted on . The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and ...

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a new initiative to significantly reduce, refine, and replace animal testing ...

Drugs have been tested on animals for over a century, but new technology may one day eliminate the need to do so. Congress and the FDA are pushing pharmaceutical companies to replace animals with ...

The National Institutes of Health (NIH) is following in the FDA’s footsteps—away from animal testing. The NIH plans to establish a new office meant to develop nonanimal methods for biomedical research ...

April 10 (UPI) --The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial intelligence, when developing monoclonal antibody therapies and ...